US 10,590,196 B2Granted

Antibodies targeting G-protein coupled receptor and methods of use

AssigneesMemorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.

InventorsRenier J. Brentjens, Eric L. Smith, Cheng Liu

Life of this patent

Estimating the term…

Abstract

The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.

Claims46

Dependent claims

An anti-human G-protein coupled receptor family C group 5 member D (GPRC5D) antibody or an antigen-binding fragment thereof, comprising:

(i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
130, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
131 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
132;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
133, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:134 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:135;
(ii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
142, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:143 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
144;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
145, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:146 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:147;
(iii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
154, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:155 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
156;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
157, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:158 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:159;
(iv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
160, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:161 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
162;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
163, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:164 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:165;
(v) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
166, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:167 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
168;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
169, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:170 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:171;
(vi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
172, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:173 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
174;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
175, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:176 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:177;
(vii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
178, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:179 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
180;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
181, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:182 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:183;
(viii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
184, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:185 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
186;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
187, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:188 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:189;
(ix) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
190, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:191 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
192;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
193, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:194 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:195;
(x) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
196, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:197 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
198;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
199, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:200 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:201;
(xi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
202, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:203 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
204;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
205, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:206 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:207;
(xii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
208, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:209 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
210;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
211, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:212 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:213;
(xiii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
214, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:215 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
216;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
217, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:218 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:219;
(xiv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
220, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:221 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
222;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
223, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:224 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:225;
(xv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
226, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:227 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
228;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
229, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:230 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:231;
(xvi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
232, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:233 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
234;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
235, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:236 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:237;
(xvii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
238, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:239 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
240;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
241, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:242 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:243;
(xviii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
244, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:245 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
246;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
247, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:248 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:249;
(xix) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
250, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:251 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
252;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
253, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:254 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:255;
(xx) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
256, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:257 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
258;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
259, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:260 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:261;
(xxi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
262, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:263 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
264;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
265, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:266 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:267;
(xxii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
292, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:293 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
294;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
295, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:296 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:297;
(xxiii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
303, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:304 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
305;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
306, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:307 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:308;
(xxiv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
316, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:317 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
318;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
319, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:320 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:321;
(xxv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
328, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:329 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
330;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
331, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:332 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:333;
(xxvi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
340, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:341 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
342;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
343, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:344 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:345;
or
(xxvii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
352, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:353 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
354;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
355, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:356 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:357.

134 more elements

An anti-human G-protein coupled receptor family C group 5 member D (GPRC5D) antibody or an antigen-binding fragment thereof, comprising:

(a) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:
5, SEQ ID NO:
13, SEQ ID NO:
21, SEQ ID NO:
25, SEQ ID NO:
29, SEQ ID NO:
33, SEQ ID NO:
37, SEQ ID NO:
41, SEQ ID NO:
45, SEQ ID NO:
49, SEQ ID NO:
53, SEQ ID NO:
57, SEQ ID NO:
61, SEQ ID NO:
65, SEQ ID NO:
69, SEQ ID NO:
73, SEQ ID NO:
77, SEQ ID NO:
81, SEQ ID NO:
85, SEQ ID NO:
89, SEQ ID NO:
93, SEQ ID NO:
298, SEQ ID NO:
310, SEQ ID NO:
322, SEQ ID NO:
334, SEQ ID NO:
346, or SEQ ID NO:
358;
and (b) a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:
6, SEQ ID NO:
14, SEQ ID NO:
22, SEQ ID NO:
26, SEQ ID NO:
30, SEQ ID NO:
34, SEQ ID NO:
38, SEQ ID NO:
42, SEQ ID NO:
46, SEQ ID NO:
50, SEQ ID NO:
54, SEQ ID NO:
58, SEQ ID NO:
62, SEQ ID NO:
66, SEQ ID NO:
70, SEQ ID NO:
74, SEQ ID NO:
78, SEQ ID NO:
82, SEQ ID NO:
86, SEQ ID NO:
90, SEQ ID NO:
94, SEQ ID NO:
299, SEQ ID NO:
311, SEQ ID NO:
323, SEQ ID NO:
335, SEQ ID NO:
347, or SEQ ID NO:
359.

53 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/614,290Filed 5 Jun 2017 · continuation
Priority: 5 Dec 2014
Published: US 2018/0118822 A13 May 2018
Granted: 17 Mar 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61P 35/00
Antineoplastic agents
C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex

Family

Application62/088,228Us provisional application · filed 5 Dec 2014
PCT/US2015/064122Parent of this continuation · filed 4 Dec 2015
US 2018/0118822 A1Pre-grant publication · published 3 May 2018
US 10,590,196 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

An anti-human G-protein coupled receptor family C group 5 member D (GPRC5D) antibody or an antigen-binding fragment thereof, comprising:

(i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
130, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
131 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
132;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
133, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:134 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:135;
(ii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
142, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:143 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
144;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
145, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:146 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:147;
(iii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
154, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:155 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
156;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
157, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:158 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:159;
(iv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
160, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:161 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
162;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
163, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:164 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:165;
(v) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
166, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:167 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
168;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
169, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:170 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:171;
(vi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
172, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:173 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
174;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
175, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:176 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:177;
(vii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
178, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:179 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
180;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
181, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:182 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:183;
(viii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
184, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:185 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
186;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
187, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:188 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:189;
(ix) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
190, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:191 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
192;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
193, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:194 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:195;
(x) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
196, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:197 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
198;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
199, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:200 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:201;
(xi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
202, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:203 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
204;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
205, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:206 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:207;
(xii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
208, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:209 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
210;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
211, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:212 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:213;
(xiii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
214, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:215 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
216;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
217, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:218 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:219;
(xiv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
220, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:221 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
222;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
223, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:224 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:225;
(xv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
226, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:227 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
228;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
229, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:230 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:231;
(xvi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
232, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:233 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
234;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
235, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:236 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:237;
(xvii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
238, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:239 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
240;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
241, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:242 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:243;
(xviii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
244, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:245 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
246;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
247, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:248 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:249;
(xix) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
250, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:251 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
252;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
253, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:254 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:255;
(xx) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
256, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:257 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
258;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
259, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:260 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:261;
(xxi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
262, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:263 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
264;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
265, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:266 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:267;
(xxii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
292, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:293 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
294;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
295, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:296 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:297;
(xxiii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
303, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:304 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
305;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
306, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:307 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:308;
(xxiv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
316, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:317 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
318;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
319, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:320 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:321;
(xxv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
328, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:329 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
330;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
331, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:332 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:333;
(xxvi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
340, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:341 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
342;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
343, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:344 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:345;
or
(xxvii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
352, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:353 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
354;
and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
355, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:356 and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:357.

134 more elements

Facts

Application

15/614,290Filed 5 Jun 2017 · continuation

Priority

5 Dec 2014

Published

US 2018/0118822 A13 May 2018

Granted

17 Mar 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61P 35/00
Antineoplastic agents
C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex